RESULTS OF PHASE II STUDY OF COMBINED IMMUNOTHERAPY WITH RITUXIMAB PLUS LYMPHOKINE‐ACTIVATED KILLER CELLS AS MAINTENANCE IN FOLLICULAR LYMPHOMA PATIENTS. (12th June 2019) - Martinez Calle, N.